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Background: GnRH-II has been shown to exert a strong antiproliferative action on tumors of the
female reproductive system. The data so far reported on the effects of GnRH-II on prostate cancer
growth are controversial. Moreover, it is still unclear through which receptor [type I or type II
GnRH-receptor (GnRH-R)] GnRH-II might modulate cancer cell proliferation.
Objective: The objective of this work was to investigate whether GnRH-II might affect the prolif-
eration of prostate cancer cells and to identify the GnRH-R throughwhich the peptidemight exert
its activity.
Design: We investigated the effects of GnRH-II on prostate cancer cell proliferation. We then
transfected PC3 cells with a small interfering RNA targeted to type I GnRH-R. After receptor si-
lencing we evaluated the effects of GnRH-II on cell proliferation and on forskolin-induced intra-
cellular cAMP accumulation. Similar experiments were performed by silencing type II GnRH-R.
Results: GnRH-II exerted an antiproliferative activity on prostate cancer cells. Transfection of PC3
cells with a type I GnRH-R small interfering RNA resulted in a significant decrease of the expression
of this receptor. After type I GnRH-R silencing: 1) the antiproliferative effect of GnRH-II was com-
pletely abrogated; and 2) GnRH-II lost its capacity to counteract the forskolin-induced cAMP ac-
cumulation. On the contrary, type II GnRH-R silencing did not counteract the antiproliferative
effect of GnRH-II.
Conclusions: GnRH-II exerts a specific and significant antiproliferative action on prostate cancer
cells. This antitumor effect is mediated by the activation of type I (but not of type II) GnRH-R and
by its coupled cAMP intracellular signalingpathway. (J Clin EndocrinolMetab 94: 1761–1767, 2009)
GnRHwas first identified as the hypothalamic key regulatorof the reproductive functions. By binding to receptors
[GnRH-receptor (GnRH-R)] on pituitary gonadotropes, GnRH
stimulates gonadotropin synthesis/secretion and, therefore, ste-
roid production from the gonads (1). GnRH agonists, when
given continuously, suppress gonadal steroid secretion through
the desensitization of pituitary GnRH-Rs; on the basis of this
activity, these compounds are successfully used for the treatment
of hormone-dependent pathologies (i.e. polycystic ovarian dis-
ease, precocious puberty, endometriosis) (2, 3), and particularly
of steroid-dependent tumors (prostate, breast, and endometrial
cancer) (4–6).
Later, it was shown that GnRH and GnRH-R are expressed
in cancer tissues to act as a local negative regulator system of
tumor growth (7–11).Wehave reported that activation of tumor
GnRH-Rs reduces the proliferation as well as the migratory/
invasive behavior of prostate cancer cells, either androgen de-
pendent or androgen independent (12–16). These observations
suggest that,whenused for the treatmentof cancers related to the
reproductive system, GnRH agonists might exert an additional,
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and more direct, antitumor activity; therefore, GnRH agonists
might represent a targeted therapeutic approach also for the
most aggressive prostate carcinoma. Clinical studies strongly
support this hypothesis (17).
More recently, a second form of GnRH (GnRH-II) has been
identified in humans (18). This form, which is encoded by a
different gene, is a decapeptide showing three amino acid dif-
ferences from the classical GnRH (now called GnRH-I).
GnRH-II is widely distributed in the central nervous system, as
well as in peripheral tissues, both normal and tumoral, suggest-
ing that it might be involved in the control of several physiolog-
ical and pathological functions (18). In particular, GnRH-II has
been more potent than GnRH-I in inhibiting the proliferation of
endometrial, ovarian, and breast cancers (19–23). In this con-
text, efforts have been made to identify the receptor that might
specifically mediate the actions of GnRH-II (type II GnRH-R).
However, no transcripts that could be translated into a conven-
tional, full-length, functional receptor have been found in hu-
mans (24, 25). Thus, it is still unclear through which receptor
(type I or II) the peptide might exert its antitumor activity.
The data so far reported on the possible effects ofGnRH-II on
prostate cancer growth are controversial (26–28). Here, we
demonstrate that GnRH-II exerts a strong antiproliferative ac-
tivityonprostate cancer cells; this effect ismediatedbyactivation
of type I GnRH-R and of its coupled cAMP intracellular signal-
ing pathway.
Materials and Methods
GnRH analogs
The GnRH-I agonist Zoladex [Goserelin acetate, D-Ser(tBu)6Aza-
Gly10-GnRH-I] was from Sigma Chemical Co. (St. Louis, MO). Human
GnRH-II (pGlu-His-Trp-Ser-His-Gly-Trp-Tyr-Pro-Gly-NH2) was from
Bachem (Heidelberg, Germany).
Cell cultures
The human androgen-dependent LNCaP and androgen-independent
DU145 and PC3 prostate cancer cell lines were obtained fromAmerican
Type Culture Collection (Rockville, MD). Cells were grown in RPMI
1640 medium (Seromed Biochrom KG, Berlin, Germany) supplemented
with fetal bovine serum (Life Technologies, Inc., Paisley, Scotland, UK)
(5%forLNCaPandDU145 cells; 10%for PC3 cells), glutamine (1mM),
and antibiotics (100 U/ml penicillin G sodium, 100 g/ml streptomycin
sulfate) in a humidified atmosphere of 5% CO2/95% air.
RT-PCR analysis
LNCaP, DU 145, and PC3 cells (2  105 cells per well) were plated
in 10-well plastic dishes. Total RNA from cells was prepared with the
RNeasymini kit (QIAGEN,Chatsworth,CA).Reverse transcriptionwas
performed on2g total RNA, and cDNAsynthesiswas performed using
the Gene AMPkit (PerkinElmer Cetus, Norwalk, CT) with an oligo(de-
oxythymidine)16 as a primer. For GnRH-II cDNA amplification, PCR
was performed for 40 cycles (95 C for 90 sec, 58 C for 90 sec, and 72 C
for 120 sec) in the presence of the primers: 5-CTGCAGCTGCCT-
GAAGGAG-3 (sense, nucleotides 1312-1330) (10 pmol) and 5-CTA-
AGGGCATTCTGGG-3 (antisense, nucleotides 2232-2250) (10 pmol)
(29). For type II GnRH-R cDNA amplification, PCR was performed in
the same experimental conditions, in the presence of the primers: 5-
CTGGCTGTGGACATCGCATGT-3 (sense, nucleotides 319-339,
exon 1) (10 pmol) and 5-ATGGCAGTCAGTGGCAGCAGA-3 (anti-
sense, nucleotides 636-656, exon 2) (10 pmol) (19). -Actin was ampli-
fiedusing specific primers.Theamplified cDNAproductswere separated
on 3% agarose gels stained with ethidium bromide and visualized under
UV light. The experiments were repeated four times. The band corre-
sponding to amplified type II GnRH-R cDNA obtained from PC3 cells
was excised from the gel and purified with the QIAquick Gel Extraction
kit (QIAGEN, Milano, Italy). The sequence of the cDNA band was
performed on an ABI 3730xl DNA analyzer automated sequencer using
version 3.1 of the Big Dye fluorescent method (Applied Biosystems, Fos-
ter City, CA). Data were analyzed with the SeqScape software version
2.1.1 (Applied Biosystems) and compared with the sequence of the hu-
man type II GnRH-R (24, 25). Sequence analysis was performed by the
DNASequencingUnit,Cogentech (Fondazione Italianaper laRicerca sul
Cancro Institute ofMolecularOncology Foundation-European Institute
of Oncology Campus, Milano, Italy).
Cell proliferation assays
LNCaP, DU 145, and PC3 cells (1  104 cells per dish) were plated
in 60-mmdishes. After 3 d, cells were treated daily with GnRH-II (109-
106M) orZoladex (106M), used as a control. After 7 d treatment, cells
were harvested and counted by a hemocytometer. Each experimental
group consistedof six replicates, and each experimentwas repeated three
times.
Type I GnRH-R silencing experiments
Type IGnRH-Rsmall interferingRNAs (siRNAs)were fromInvitrogen
(Burlington, Ontario, Canada). Their sequences were: type I GnRH-R-S
(5-UUGCAGAGUAACUCUCCAGCAUACC-3) and type IGnRH-R-AS
(5-GGUAUGCUGGAGAGUUACUCUGCAA-3). A nonspecific scram-
bled siRNAwas used as a control (MediumGCDuplex; Invitrogen). Trans-
fectionswereperformedusingLipofectamineRNAiMax(Invitrogen)as the
transfectant (according to the manufacturer’s instructions). Efficiency of
transfection was assessed using the block-it Alexa fluor red fluorescence
oligo.Transfectionefficiencywasusuallyhigher than70%oftotal cells.The
effectiveknockdownof type IGnRH-Rafter siRNAtransfectionswasmon-
itored by RT-PCR, Western blot, and immunofluorescence analysis.
RT-PCR analysis
PC3 cells were seeded in 60-mmdishes (2 105 cells per dish). Three
days later, cells were transfected with type I GnRH-R siRNA or with
scrambled siRNA (70 nM, final concentration) for 24 h. Reverse tran-
scriptionwasperformedon totalRNA,asdescribedpreviously. PCRwas
performed for 33 cycles (94 C for 60 sec, 59 C for 60 sec, 72 C for 120
sec), in the presence of the primers: upstream primer, 5-GACCTT-
GTCTGGAAAGATCC-3 (50 pmol) and downstream primer 5-CAG-
GCTGATCACCACCATCA-3 (50 pmol) (30). The amplified cDNA
products were separated on 1.5% agarose gels stained with ethidium
bromide and visualized under UV light. The experiments were repeated
three times.
Western blot analysis
PC3 cells were seeded in 10-cm dishes (1.5 106 cells per dish) and
transfected, 2d later, as describedpreviously.After either24or48h, cells
were lysed in radioimmunoprecipitation assay buffer [0.05 M Tris-HCl
(pH7.7), 0.15MNaCl, 0.8%sodiumdodecyl sulfate, 10mMEDTA, 100
MNaVO4,50mNaF,0.3mMphenylmethylsulfonyl fluoride, and5mM
iodoacetic acid] containing leupeptin (50g/ml), aprotinin (5l/ml), and
pepstatin (50 g/ml). Whole cell extracts (30 g) were resuspended in
sample buffer [0.5 M Tris-HCl (pH 6.8), 20% glycerol, 10% sodium
dodecyl sulfate, and 0.05% blue bromophenol] and heated at 95 C for
5 min. After electrophoretic separation by 10% SDS-PAGE, proteins
were transferred onto nitrocellulose membranes. Membranes were
blocked in 3%BSAbefore incubation at room temperature, for 2 h, with
either the mouse monoclonal type I GnRH-R antibody (1.5 g/ml)
(Clone F1G4; LabVisionCorp., Fremont, CA) or themousemonoclonal
type II GnRH-R antibody (1:500) (67-R:sc-100301; Santa Cruz Bio-
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technology, Inc., Santa Cruz, CA). Detection was done using a horse-
radish peroxidase-conjugated antimouse secondary antibody and en-
hanced chemiluminescence reagents (SuperSignal Chemiluminescence
Detection System; Pierce, Rockford, IL). Actin expression was detected
with mouse antihuman actin (1:10,000) as the primary antibody (clone
Ab-1; Oncogene, San Diego, CA). The experiments were repeated three
times.
Immunofluorescence analysis
PC3 cells were seeded on 13-mm-diameter coverslips. After 2 d, cells
were transfected, as described previously. After transfection (48 h), cells
were fixedwith3%paraformaldehyde in2%sucrose-PBS for10minand
incubated with the unlabeled monoclonal antitype I GnRH-R primary
antibody (1:100) (Clone A9E4; Lab Vision Corp.), followed by fluores-
cein isothiocyanate-conjugated goat antimouse secondary antibody (Al-
exa Fluor 488; Molecular Probes, Inc., Eugene, OR). Labeled cells were
examined under a Zeiss Axiovert 200 microscope (Carl Zeiss MicroIm-
aging, Inc., Thornwood, NY) with a 63 1.4 objective lens linked to a
CoolSNAP Es charge-coupled device camera (Roper Scientific-Crisel In-
struments, Rome, Italy). Images were acquired using the MetaVue pro-
gram (Molecular Devices, Sunnyvale, CA) and analyzed using Adobe
Photoshop 6.0 (Adobe Systems, Inc., San Jose, CA). Each staining was
repeated three times for three different preparations for each group.
Cell proliferation studies after type I GnRH-R silencing
PC3 cells were seeded (3 104 cells per well) in 24-multiwell plates
and transfected with either type I GnRH-R siRNA or scrambled siRNA.
After 2 d, cells were treatedwithGnRH-II (106 M) or Zoladex (106 M)
for 48 h. Cells were harvested and counted by a hemocytometer. Each
experimental condition was replicated six times, and each experiment
was repeated three times.
cAMP determination studies after type I GnRH-R
silencing
PC3 cells (3  106 cells per well) were transfected with either type I
GnRH-R siRNA or scrambled siRNA. After 2 d, cells were washed with
serum-free medium and pretreated for 1 h with GnRH-II (106 M) or
Zoladex (106 M). Cells were treated with 3-isobutyl-1-methylxantine
(0.5 mM) (Sigma Chemical) for 15 min at 37 C before the addition of
forskolin (FSK) (5 mM, 15 min). Cells were extracted with ethanol 65%
at 4C for 5min and centrifuged. The supernatants were dried and stored
at20 C. cAMP content was determined by the 3H-cAMP assay system
(Amersham Pharmacia Biotech, Buckinghamshire, UK).
Each experimental condition was replicated six times, and each ex-
periment was repeated three times.
Type II GnRH-R silencing experiments
Type IIGnRH-RsiRNAswere fromInvitrogen.Their sequenceswere
as follows: type II GnRH-R-S, 5-ACAAACUUACUGUUCAGCAU-
CAUAU-3; and type II GnRH-R-AS, 5-AUAUGAUGCUGAACAGU-
AAGUUUGU-3. A nonspecific scrambled siRNAwas used as a control
(Low GCDuplex; Invitrogen). Transfections were performed as de-
scribed for type I GnRH-R silencing. The efficiency of type II GnRH-R
knockdown was monitored by RT-PCR, as described for type II
GnRH-R mRNA amplification. The experiments were repeated three
times.
Cell proliferation studies after type II GnRH-R silencing
PC3 cells (3 104 cells per well) were transfected with either type II
GnRH-R siRNA or scrambled siRNA. After 2 d, cells were treated with
either GnRH-II (106 M) or Zoladex (106 M) for 48 h. Cells were then
harvested and counted by a hemocytometer. Each experimental condi-
tion was replicated six times, and each experiment was repeated three
times.
Statistical analysis
Data from proliferation and from cAMP determination studies were
analyzed by one-way ANOVA followed by Bonferroni’s test.
Results
Expression of GnRH-II and type II GnRH-R in prostate
cancer cells
The expression of GnRH-II mRNA in prostate cancer cells
was analyzed by RT-PCR using a specific set of oligonucleotide
primers (29). Figure 1A shows that the predicted 199-bp cDNA
was detected in human immortalized PNT1A prostate epithelial
cells (nontumoral control), and in prostate cancer cells, an-
drogen dependent (LNCaP) or androgen independent (DU
145 and PC3).
The expression of type II GnRH-R was investigated as pre-
viously described (19). After RT-PCR, an amplified cDNA band
of the expected length (338 bp)was obtained in PNT1Aprostate
cells, aswell as in LNCaP,DU145, and PC3prostate cancer cells
(Fig. 1B). The expression of the receptor was particularly high in
PC3 cells. In these cells, analysis of the nucleotide sequence of the
obtained cDNA revealed identity with the reported sequence of
the human type II GnRH-R cDNA (31, 32).
Effects of GnRH-II on prostate cancer cell proliferation
LNCaP, DU 145, and PC3 prostate cancer cells were treated,
daily, for 7 dwithGnRH-II (109-106M). TheGnRH-I agonist
Zoladex (106 M) was used as a control. Figure 2 shows that
GnRH-II reduces the proliferation of the three cell lines in a
dose-dependent way. The antiproliferative effect of GnRH-II
was significant at the doses of 108 -106 M. As expected, Zo-
ladex (106 M) significantly decreased the proliferation of the
three cell lines (Fig. 2). The inhibitory effect of both GnRH-II
(106 M) andZoladex (106 M)was completely abrogatedwhen
prostate cancer cells (PC3) were cotreated with the GnRH-I an-
tagonist Antide (106 M; data not shown).
Efficiency of type I GnRH-R silencing
It is still unclear through which GnRH-R (type I or II)
GnRH-II might exert its effects on cancer cells. The siRNA
A
PNT1A LNCaP DU145 PC3
GnRH-II
β-actin
B
type II
GnRH-R
β-actin
PNT1A LNCaP DU145 PC3
FIG. 1. Expression of GnRH-II (A) and type II GnRH-R (B) in normal immortalized
prostate epithelial cells (PNT1A), as well as in prostate tumor cells (LNCaP, DU
145, and PC3). Total RNA was extracted from the cells and submitted to RT-PCR
in the presence of the oligonucleotide primers specific for GnRH-II and type II
GnRH-R, respectively. One representative of four different experiments is shown
here. -Actin mRNA expression was analyzed as a control.
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technique was used to clarify the role of type-I GnRH-R in
mediating the antiproliferative activity ofGnRH-II in prostate
cancer cells. These experiments were performed in PC3 cells,
which showed a high level of expression of type II GnRH-R
(Fig. 1B).
Transfection of siRNA resulted in a significant decrease of
type I GnRH-RmRNA levels at 24 h (Fig. 3A). Silencing of type
I GnRH-R was also followed by a significantly reduced expres-
sion of the receptor protein (Western blot analysis, Fig. 3B). The
efficiency of the transfection was particularly clear at 48 h after
receptor knockout. Immunofluorescence analysis of type I
GnRH-R revealed a strong positive reaction in PC3 cells trans-
fected with scrambled siRNA (Fig. 3C). Conversely, immuno-
fluorescence stainingwas significantly reduced in type IGnRH-R
siRNA transfected PC3 cells. These observations demonstrate
that type I GnRH-R knockout efficiently reduces the expression
of the receptor. Silencing of type I GnRH-R did not affect the
expression of type II GnRH-R (Fig. 3D).
Effects of type I GnRH-R silencing on the
antiproliferative activity of GnRH-II
PC3 cells were transfected with either a scrambled siRNA or
type IGnRH-RsiRNAand treatedwith eitherGnRH-II (106M)
or Zoladex (106 M) for 48 h. As expected, in untransfected
control cells, as well as in cells transfected with the scrambled
siRNA, both GnRH-II and Zoladex significantly reduced cell
number (Fig. 4, A and B). The antiproliferative effect of both
compounds was completely abrogated in PC3 cells transfected
with type I GnRH-R siRNA (Fig. 4C).
Effects of type I GnRH-R silencing on cAMP
accumulation
We have previously showed that, in prostate cancer cells,
type IGnRH-R is coupled to theGi-cAMP signaling pathway
(33). To confirm the role of this receptor in mediating the
antiproliferative activity of GnRH-II, we investigated the ef-
fects of GnRH-II on FSK-induced cAMP accumulation in PC3
cells, after type I GnRH-R knockout. PC3 cells were trans-
fected with either a scrambled siRNA or type I GnRH-R
siRNA, and treated with FSK in the presence of GnRH-II
(106 M) or Zoladex (106 M). Figure 5A shows that both
GnRH-II and Zoladex significantly counteract the cAMP ac-
cumulation induced by FSK in untransfected PC3 cells. Similar
results were obtained in cells transfected with the scrambled
siRNA (Fig. 5B). On the other hand, both GnRH-II and Zo-
ladex failed to antagonize FSK-induced cAMP accumulation
after knockout of type I GnRH-R (Fig. 5C).
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FIG. 2. Effects of GnRH-II on the proliferation of prostate cancer cells, either
androgen dependent (A, LNCaP), or androgen independent (B, DU 145; C, PC3).
Cells were treated daily, for 7 d, with either GnRH-II (109 -106 M) or Zoladex
(106 M), used as the control. After the treatment, cells were harvested and
counted by a hemocytometer. Each experimental group consisted of six
replicates, and each experiment was repeated three times. The data were
analyzed by ANOVA followed by Bonferroni’s test. Values are represented as the
mean  SE. *, P  0.05 vs. untreated controls (C).
FIG. 3. Effects of type I GnRH-R silencing on the expression of type I GnRH-R,
both at the mRNA (A) and protein (B and C) level, and on the expression of type
II GnRH-R, at the protein level (D). A, PC3 cells were transfected with either the
scrambled siRNA or type I GnRH-R siRNA. After transfection (24 h), RT-PCR was
performed in the presence of specific oligonucleotide primers. -Actin mRNA is
reported as a loading control. One representative of three different experiments
is shown. 1, untransfected controls; 2, PC3 cells transfected with the scrambled
siRNA; and 3, PC3 cells transfected with type I GnRH-R siRNA. B, PC3 cells were
transfected with either a scrambled siRNA or type I siRNA. After either 24 or
48 h, Western blotting was performed on whole cell extracts, using a mouse
monoclonal type I GnRH-R antibody. Actin expression was analyzed as a loading
control. One representative of three different experiments is shown. 1,
untransfected controls; 2, PC3 cells transfected with the scrambled siRNA; and 3,
PC3 cells transfected with type I GnRH-R siRNA. C, PC3 cells were transfected
with either the scrambled siRNA or type I GnRH-R siRNA. After transfection (48
h), cells were fixed and incubated with the unlabeled monoclonal antitype I
GnRH-R primary antibody, followed by fluorescein isothiocyanate-conjugated
goat antimouse secondary antibody. One representative of three different
experiments is shown here. Scale bar, 10 m. Dapi, 4,6-diamidino-2-
phenylindole. D, PC3 cells were transfected with either the scrambled siRNA or
type I GnRH-R siRNA. After 48 h, Western blotting was performed on whole cell
extracts, using a mouse monoclonal type II GnRH-R antibody. Actin expression
was analyzed as a loading control. One representative of three different
experiments is shown. 1, untransfected controls; 2, PC3 cells transfected with the
scrambled siRNA; and 3, PC3 cells transfected with type I GnRH-R siRNA.
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Effects of type II GnRH-R silencing on the
antiproliferative activity of GnRH-II
Our results indicate that GnRH-II reduces the proliferation of
prostate cancer cells through the activation of type I GnRH-R.
However, according to Enomoto and Park (26), the two receptors
(types I and II) might interact inmediating the activity of GnRH-II.
To clarify this issue, we studied whether type II GnRH-R silencing
might affect the antiproliferative activity of GnRH-II. PC3 cells
were transfected with a type II GnRH-R siRNA; the efficiency of
transfection was monitored by RT-PCR. Treatment with siRNA
resulted in a significant decrease of type II GnRH-R mRNA levels
at 24 h after transfection (Fig. 6, upper panel).
To clarify the effects of type II GnRH-R silencing on cell pro-
liferation,PC3cellswere transfectedwitheitherascrambledsiRNA
or type II GnRH-R siRNA.Cells were treatedwith eitherGnRH-II
(106 M) or Zoladex (106 M) for 48 h. Both compounds exerted
a significant antiproliferative effect, not only on control cells or on
cells transfected with the scrambled siRNA, but also on cells in
which type IIGnRH-Rhadbeensilenced (Fig.6,A–C, lowerpanel).
This demonstrates that the antimitogenic activity of GnRH-II on
prostate cancer cells is not mediated by type II GnRH-R.
Discussion
The direct antiproliferative effects of GnRH-I and its analogs on
different tumors, includingprostate cancer, arewell documented
(7–11). On the other hand, clear evidence about the possible
action of the second form of GnRHon prostate cancer growth is
still lacking.
In this study we analyzed the effects of GnRH-II on prostate
cancer cell proliferation and unraveled its mechanism of action.
First, we demonstrated that GnRH-II is expressed in human
prostate epithelial cells, both nontumoral (PNT1A) and tumoral
(LNCaP, DU 145, and PC3). No associationwas found between
the level of expression of the peptide and the grade of malig-
nancy; this observation is consistent with previous reports (28).
In all the cell lines tested, we demonstrated the presence of a
mRNA specific for type II GnRH-R. The amplified cDNA
spanned from nucleotide 319 (exon 1) to nucleotide 656 (exon
2). Sequence analysis of this 338-bp fragment revealed a com-
plete identity with the reported sequence of the human type II
GnRH-R (31, 32). This indicates that a transcript specific for
type II GnRH-R is expressed in prostate cancer cells. These ob-
servations are in agreement with those previously reported by
Enomoto and Park (26). The expression of type II GnRH-R has
also been reported for other tumors, such as breast (22), endo-
metrial, and ovarian (19, 34) cancer. However, it has been pro-
posed that a full-length functional receptor protein does not exist
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controls. B, PC3 cells transfected with the scrambled siRNA. C, PC3 cells transfected
with type I GnRH-R siRNA. *, P 0.05 vs. untreated controls (C).
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FIG. 5. Effects of type I GnRH-R silencing on cAMP accumulation. PC3 cells were
transfected with either the scrambled siRNA or type I GnRH-R siRNA. After 2 d,
cells were pretreated (1 h) with either GnRH-II (106 M) or Zoladex (106 M).
Cells were then treated with 3-isobuthyl-1-methylxantine, phosphodiesterase
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repeated three times. A, Untransfected controls. B, PC3 cells transfected with
the scrambled siRNA. C, PC3 cells transfected with type I GnRH-R siRNA.
Values are represented as the mean  SE. *, P  0.05 vs. untreated controls
(C); **, P  0.05 vs. FSK-treated cells.
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in humans because of the presence of a frameshift and a prema-
ture stop codon in the receptor transcript (24, 25). Thus, the
effects of GnRH-II on cancer growth might be mediated by type
I, rather than type II, GnRH-R.
To clarify this issue,we investigated the effects ofGnRH-II on
prostate cancer cell proliferation and the receptor (type I or II)
thatmightmediate these effects.Wedemonstrated thatGnRH-II
exerts a dose-dependent antiproliferative action on prostate can-
cer cells, either androgen dependent (LNCaP) or androgen in-
dependent (DU 145, PC3). To identify the receptor that might
mediate the antitumor activity of GnRH-II, we used the siRNA
technique. PC3 cells were transfected with a siRNA targeted
against the type IGnRH-Rgeneorwith a siRNAtargeted against
type II GnRH-R. Type I GnRH-R silencing completely antago-
nized the antiproliferative effects of GnRH-II, as well as that of
the GnRH-I agonist Zoladex, as expected. On the other hand,
type II GnRH-R silencing did not affect the antiproliferative ac-
tion of GnRH-II. These results strongly indicate that the anti-
proliferative effect of GnRH-II on prostate cancer cells is medi-
ated by type I, but not type II, GnRH-R.
The data so far reported in the literature regarding the recep-
tor that specifically mediates the activity of GnRH-II in tumor
cells are controversial. Our results are in agreement with those
published by Kim et al. (34). These authors demonstrated that,
in ovarian cancer cells, GnRH-II exerts an antimitogenic action
through the activation of type I GnRH-R. However, contrasting
results were obtained by other authors. Enomoto and Park (26)
reported that, in DU 145 cells, type II GnRH-R mediates the
antiproliferative action of GnRH-II, through a direct interaction
with type I GnRH-R. Grundker et al. (20) showed that GnRH-II
significantly reduces the growth of endometrial and ovarian can-
cer cells; this effect persists after knockout of type I GnRH-R,
suggesting the existence, in these cells lines, of a functional type
II GnRH-R. Gunthert et al. (22) demonstrated that GnRH-II
analogs inhibit the proliferationof breast cancer cells, expressing
type IIGnRH-R;however,whether this receptormight be crucial
for theantimitogenic activityofGnRH-IIwasnot investigatedby
these authors. The reasons for these discrepancies are unclear;
however, as suggestedbyKim et al. (34), theymightbeaccounted
for by the different experimental conditions adopted (cell lines,
methods for type I GnRH-R silencing, etc.).
In the present paper, we also show that GnRH-II, as well as
GnRH-I agonists, counteract the FSK-induced intracellular
cAMP accumulation; these data confirm our previous reports
showing that type I GnRH-R is coupled to the Gi-cAMP sig-
naling pathway in prostate cancer cells (33). In ovarian cancer
cells, Kim et al. (34) demonstrated that GnRH-II, by binding to
type I GnRH-R, activates ERK1/2 through a protein kinase C-
dependent pathway. The intracellular events that follow type I
GnRH-R activation in cancer cells have been extensively inves-
tigated. In addition to the Gi-cAMP (7, 33, 35) and protein
kinase C-ERK signaling pathways (34), GnRH-I analogs have
acted through activation of c-Jun N-terminal kinase, p38 stress-
activatedkinases, phosphotyrosinephosphatases, and inhibition
of the phosphatidylinositol 3-kinase/Akt (11, 36, 37). These sig-
nals are distinct from those reported to mediate the stimulatory
activity of GnRH-I at the pituitary level. On gonadotrope cells,
type I GnRH-R is known to be coupled to the Gq-phospho-
inositide-phospholipase C pathway (24, 25, 38, 39). To explain
this complex scenario, Millar et al. (40) have proposed the “li-
gand-induced selective-signaling” phenomenon. According to
this concept, type I GnRH-R might assume various conforma-
tions, endowed with different selectivities for GnRH-I analogs
and with different intracellular signaling pathways. Thus, each
GnRH-I analog can recruit particular pathways,while bypassing
others (40). As underlined by the authors, this might be crucial
for opening the way to the development of newGnRH-I analogs
that might improve anticancer therapeutic interventions.
In summary, in the present paper, we demonstrate that both
GnRH-II anda type IIGnRH-Rtranscript are expressed inprostate
cancer cells.GnRH-II exertsa significantantiproliferativeactionon
prostate cancer cells; this effect is mediated by type-I GnRH-R and
by its coupled cAMP intracellular signaling pathway.
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FIG. 6. Upper panel, Effects of type II GnRH-R silencing on the expression of the
receptor, at the mRNA level. PC3 cells were transfected with either the scrambled
siRNA or type II GnRH-R siRNA. After transfection (3 d), RT-PCR was performed in
the presence of specific oligonucleotide primers. -Actin mRNA is reported as a
loading control. One representative of three different experiments is shown. 1,
untransfected controls; 2, PC3 cells transfected with the scrambled siRNA; and 3,
PC3 cells transfected with type II GnRH-R siRNA. Lower panel, Effects of type II
GnRH-R silencing on the antiproliferative activity of GnRH-II. PC3 cells were
transfected with either the scrambled siRNA or type II GnRH-R siRNA. After 3 d,
cells were treated with either GnRH-II (106 M) or Zoladex (106 M) for 48 h. At
the end of the treatment, cells were counted by a hemocytometer. Each
experimental condition was replicated six times, and each experiment was
repeated three times. The data were analyzed by ANOVA followed by
Bonferroni’s test. Values are represented as the mean  SE. A, Untransfected
controls. B, PC3 cells transfected with the scrambled siRNA. C, PC3 cells
transfected with type II GnRH-R siRNA. *, P  0.05 vs. untreated controls (C).
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